Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational, multicentre, randomized, open-label, paralle...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Heart J
Asıl Yazarlar: Hohnloser, Stefan H, Camm, John, Cappato, Riccardo, Diener, Hans-Christoph, Heidbüchel, Hein, Mont, Lluís, Morillo, Carlos A, Abozguia, Khalid, Grimaldi, Massimo, Rauer, Heiko, Reimitz, Paul-Egbert, Smolnik, Rüdiger, Mönninghoff, Christoph, Kautzner, Josef
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Fast Track Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6754569/
https://ncbi.nlm.nih.gov/pubmed/30976787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehz190
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller